Time is Limited - Act Now
Learn more about the history of Tasigna® and the alleged failures of its parent company Novartis®
Tasigna® (nilotinib) is a prescription drug that is often prescribed to treat chronic myeloid leukemia (CML).
Accounting for about 15% of all adult leukemia cases, CML is a type of cancer that begins deep in the bone marrow and travels throughout the bloodstream.
Tasigna® is a relatively new drug that was developed by Novartis® and approved for use in the treatment of CML in 2007–it works by blocking certain proteins that cause leukemia cancer cells to grow.
Tasigna® has become a very profitable drug for Novartis® since its original release–however, shortly after its first release, Tasigna® was associated with adverse incident reports indicating that the drug could be the cause of serious cardiovascular problems in some patients.
In 2011, the results of several studies reported that the use of Tasigna® was causing some patients to develop accelerated atherosclerosis–a condition in which the arteries delivering blood from the heart become hardened and narrow.
Typically, atherosclerosis develops gradually over time as a person ages–however, certain patients using Tasigna® began developing atherosclerosis within a few months.
Atherosclerosis can be very dangerous as it can result in serious cardiac and vascular events such as heart attack, or peripheral arterial disease.
In Canada, Novartis® amended its prescribing information to include a warning that Tasigna® can cause rapidly evolving vascular disease in some patients–however, Novartis® allegedly deliberately elected to preclude this critical warning from Tasigna® prescribing information in the United States.
In fact, the U.S. drug label for Tasigna® still does not contain any information about the risk of atherosclerosis.
Under certain circumstances, victims who suffer from unmarked Tasigna® side effects can pursue compensation for their losses.
Learn about Tasigna®-induced atherosclerosis and the potential for claiming compensation
Additional research efforts suggest a strong chance that Tasigna® is linked to atherosclerotic-related events, including stroke and heart attack.
While many patients taking Tasigna® are at a higher risk for atherosclerosis, the connection in many cases will be obvious because the medical literature describes an association between Tasigna® and a rare form of accelerated atherosclerosis.
According to the research concerning Tasigna®-induced atherosclerosis:
- Atherosclerosis generally develops over an extended time, taking years to become an acute risk.
- Rapid progression or sudden aggravation of atherosclerosis is uncommon.
- Tasigna®-induced atherosclerosis often develops much more quickly, giving doctors less time to diagnose and combat the condition.
A growing population of patients who have developed rapid atherosclerosis from using Tasigna® and suffered serious injuries has filed lawsuits against Novartis®.
The lawsuits allege that Novartis® allegedly knew as early as 2010 that Tasigna® could potentially cause accelerated atherosclerosis and/or other related conditions.
Novartis® allegedly knowingly and intentionally failed to warn about these risks in the U.S. in order to protect its financial interests.
August 2021 Update: On August 12, 2021, the United States Judicial Panel on Multidistrict Litigation ordered the creation of a Tasigna® class action lawsuit for claims involving this therapy.
December 2021 Update: A new study published this fall in the journal of Cardiology-Oncology identified a clear link between the use of Tasigna® and vasospastic angina–this is yet another potentially dangerous side-effect linked to the low blood flow problems caused by Tasigna®.
The Shield Justice Watch team encourages those suffering after taking Tasigna® to request a free, private case evaluation for justice and compensation!
Our network of attorneys are ready to support you.
IS THERE A CASE?
Answer a brief, private online questionnaire that asks for key details of the experience
Have the case evaluated by a legal team free of charge without any obligation to file
GET STARTED NOW
Depending on the circumstances, the case could be filed for potential compensation
Please seek the advice of a medical professional before making health care decisions. This advertisement is not associated with Tasigna® or any government agency.
www.shieldjusticewatch.com is the property of Shield Legal LLC. 1530 Faraday Ave, Suite 200 Carlsbad, CA 92008
This website is not part of the Facebook website or Facebook, Inc. Additionally, this site is NOT endorsed by Facebook in any way. FACEBOOK is a trademark of FACEBOOK, INC.
ATTORNEY ADVERTISING. This Website is not intended to provide medical advice. Consult your doctor or physician before starting or stopping any medication.
Discontinuing a prescribed medication without your doctor’s advice can result in injury or death. are not an indication of future results. Every submission is evaluated on its own facts and circumstances. Valuation depends on facts, injuries, jurisdiction, venue, witnesses, parties, and testimony, among other factors. No representation is made that the quality of legal services to be performed is greater than the quality of legal services performed by other lawyers. Shield Justice Watch does not itself provide legal services. Submission will be referred to third party attorneys and law firms. Do not rely on this advertisement in making any medical decision. Please call your physician before making any medical decision, including altering your use of any drug. Court costs and expenses may be the responsibility of the client. Not available in all states. This advertisement is not intended as a testimonial, endorsement or dramatization, and does not constitute a guarantee, warranty, or prediction regarding the outcome of your legal matter, either expressed or implied. Anyone considering a lawyer should independently investigate the lawyers' credentials and ability, and not rely upon advertisements or self-proclaimed expertise. Only persons age 18 or older have permission to access our Service. Our Service does not address anyone under the age of 13("Children").
©2021 Shield Justice Watch